<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

4 min read

This Week in Ortho: Projecting the Market's COVID-19 Recovery

By Thomas Wallick on 6/1/20 6:53 PM

As access to healthcare continues to open up, the orthopedic industry is taking significant precautions to insure the health, safety and piece of mind of patients and caregivers and balance that with its attempt to ramp up services and procedures. The following is a small sampling of the orthopedic updates compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present the most relevant news to our subscribers:

Updated Survey Data Points to Recovery by Q420

WFS’ new survey of 623 US-based physicians (15 specialties) shows that in orthopedic, the % of procedures expected to be postponed due to COVID-19 for both TKR and THR declined from 94% (Wave 1) to 85% (Wave 2). WFS MedTec: Updated Survey Data Points to Recovery by Q420

Impact of COVID-19 on the Spine Market

Of deferred spinal fusion procedures, surveyed surgeons now expect 74% of cases to be performed at a later date w/ 26% cancelling. Reasons for cancellation include pt seeking treatment w/ a different surgeon (26%) and underlying condition improving (23%). WFS MedTech Survey

Robotic Procedures Affected by COVID-19

Based on its survey of 623 US-based physicians across 15 specialties between April 27 and May 8, WFS notes that in general the % of robotic & laparoscopic procedures across all specialties declined compared to pre-COVID 19 levels, while the % of open procedures increased.

Continue Reading
5 min read

Biomedical Solutions: An Interview with DSM Biomedical's John Witkowski

By Kim French on 5/20/20 10:00 AM

SmartTRAK discusses the latest advancements in biomedical solutions with DSM President John Witkowski

DSM, a global leader in biomedical solutions for more than 30 years, helps improve the health of 3.5 million patients annually. While biomaterials have been around for decades, DSM Biomedical is advancing biomaterial science, providing the latest synthetic biomaterials and stem cell-based technologies that are used in various applications, including spine, general orthopedics, sports medicine, general surgery and wound.

To learn more about the latest advancements in DSM Biomedical biomaterials and technologies and what’s next for the business, click on the following video to listen to SmartTRAK’s interview with John Witkowski, President of DSM Biomedical. A transcript of the interview can also be downloaded below. 

Continue Reading
3 min read

Weathering the COVID-19 Storm in Orthobiologics: An Interview with Steven Sampson, DO

By Freddy Buntoum on 5/11/20 9:00 PM

The COVID-19 pandemic is having a significant effect on physician practices in Orthopedics and Sports Medicine, including the number of elective procedures being postponed, when normal operations might resume, the adoption of telemedicine, delivery of physician education and interactions with industry. To find out more, SmartTRAK Analyst Freddy Buntoum interviewed Steven Sampson, DO, founder of The Orthobiologic Institute (TOBI) and an internationally-recognized expert in the field of non-surgical orthopedics and the science of sports medicine. To hear Dr. Sampson’s take on how things might evolve throughout the rest of 2020, and how his practice and organization are supporting patients and other stakeholders, click on the following video to listen to the interview recorded via Uberconference (25:20 minutes). A transcript of the interview can be downloaded below.

Continue Reading
3 min read

Q419/FY19 Soft Tissue Fixation Market Recap: Overall Positive Growth

By Freddy Buntoum on 4/29/20 9:21 AM

For the fourth quarter of 2019, WW Soft Tissue Fixation Market revenue was up +3.7% YoY. Aggregate growth for the quarter especially benefited from healthy and continued revenue gains in the Hip Labral repair segment, which was up +8.9% YoY. And, to a smaller extent, the Meniscal repair and the Shoulder repair segments also contributing to the overall WW market growth in Q419 with YoY increases of 4.4% and 4.1%, respectively, based on SmartTRAK Financial Dashboard. Similar to other orthopedic markets, such as the Joint replacement market, Soft Tissue Fixation is typically seasonal with lower sales during Q3 and recovery in Q4 driven by a year-end increase in the number of elective procedures and stronger product push as competitors race to finish the year at or above their respective budget projections.

Continue Reading
4 min read

Q419/FY19 Orthobio Market Recap: Decelerating Growth

By Kim French on 4/3/20 9:46 AM

Surprises lead to deceleration of overall Orthobio growth

For Q419, US Orthobio market growth (comprised of Bone, Cartilage, Soft Tissue and Meniscus Replacement implants) was flat at 0.3%. FY19 grew 4.2% over 2018. Both Q4 and FY19 did see shifts within the market. The double-digit growth of Cartilage and Wright’s AUGMENT was offset by lower than expected sales in InfuseCartiva SCI and soft tissue augmentation. For 2019, Medtronic remained the overall US market leader, followed by DePuy Synthes and Stryker.

Among the many topics covered in the comprehensive Q419/FY19 OrthoBio Market Recap* are:

Continue Reading
1 min read

Q419/FY19 US Joint Fluid Market Recap: Stronger Demand for Single Injection

By Freddy Buntoum on 3/16/20 2:14 PM

Overall, 2019 was a good recovery year for the US Joint Fluid market with Single-injection treatment options at the helm

For Q419, revenue in the US Joint Fluid market was up, recovering fairly well from a year ago according to SmartTRAK Financial Dashboard. Aggregate growth for the quarter was attributable to a double-digit revenue growth in single injection. Stronger demand and heavy product push in that segment, especially at year-end, was offset to a certain extent by revenue declines in 3- and 5-injections. 

Among the many topics covered in the comprehensive Q419 US Joint Fluid Market Recap* are:

Continue Reading
7 min read

SmartTRAK Highlights Recent Studies in OrthoBio

By Lindsey Wolejko on 2/27/20 9:30 AM

Here are some highlights of recently announced trials in OrthoBio that were picked up by our analysts, posted on SmartTRAK, and included in our Daily Updates email.
 

A 76-pt study is underway evaluating if pts who receive a bioinductive graft (REGENETEN) have better function and fewer re-tear at 1-yr post-op vs those who received a debridement alone. Anticipated completion date is 9/23. clinicaltrials.gov

A 30-pt double blind, randomized, split mouth study was initiated evaluating the non-inferiority of Fibro-Gide in comparison to connective tissue graft for the tx of Miller Class I or II recession defects at 6 mos post tx. clinicaltrials.gov

Find out more about SmartTRAK Daily Updates

Continue Reading
3 min read

Q319 Trauma Market Recap: Easy YoY Comparisons Support Sequential Gains

By Natasha Weeks on 12/19/19 9:30 AM

Easy YoY comps along with new product introductions help drive sequential growth 

SmartTRAK reports that In Q319, the WW Trauma Market (defined as fixation of the pelvis, femur & proximal/shaft portion of the tibia) increased +3.7% (as reported), with the US posting +4.6% growth. Q319 WW share leaders remained relatively steady compared to last year, with top trauma player DePuy Synthes, followed by Stryker, Zimmer Biomet and Smith & Nephew. The WW Trauma Market Segment shares were...

Among the many topics covered in the complete, comprehensive  Q319 Trauma Market Recap*  are:
Continue Reading
4 min read

Q319 OrthoBio Market Recap: Healthy YoY Growth

By Kim French on 12/16/19 9:30 AM

With a boost from an extra selling day during the third quarter, the US OrthoBio Market continues to be healthy, with Q319 revenue up +5.8% YOY. Year-to-date revenue is up +5.5% compared to the same time period for 2018. In addition to the specific factors that were discussed in the Q219 OrthoBio Recap, the segment’s success may be attributed to robustness in the broader economy and more people feeling comfortable scheduling procedures. As reported in Needham’s Q319 Review, in Q319 vs. Q219, overall orthopedic market growth improved to 5.0% vs. 3.1%, with spine improving to ...

Among the many topics covered in the complete, comprehensive Q319 OrthoBio Market Recap* are:
Continue Reading
7 min read

TOBI 2019 Update: Issues & Trends in Orthobiologics

By Freddy Buntoum on 11/11/19 3:56 PM

SmartTRAK's Senior Regenerative Medicine Analyst, Freddy Buntoum, attended TOBI 2019 this summer. Here's a look at some of the key trends and takeaways in Orthobiologics from the 10th PRP & Regenerative Medicine Symposium, hosted by TOBI, that are still prevalent today.

Continue Reading

    Recent Articles